OncoMatch/Clinical Trials/NCT05873699

Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection

Is NCT05873699 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Hyperpolarized 13-C-pyruvate for pancreatic cyst.

Phase 1RecruitingM.D. Anderson Cancer CenterNCT05873699Data as of May 2026

Treatment: Hyperpolarized 13-C-pyruvate — To learn if Hyperpolarized C-Pyruvate Magnetic Resonance (HP-MR) Spectroscopic Imaging can help doctors detect low-risk (benign) and high-risk (malignant) cysts.

Check if I qualify

Eligibility summary

For patients with pancreatic cyst.

This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.

US trial sites

M D Anderson Cancer Center · Houston, Texas

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify